Advanced treatment for locally advanced cervical cancer using image-guided techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on improving the treatment of locally advanced cervical cancer through the use of image-guided adaptive brachytherapy (IGABT) combined with radiochemotherapy. It aims to enhance local tumor control and minimize adverse reactions to surrounding organs by employing advanced imaging techniques and treatment protocols. The study builds on previous findings from the EMBRACE study and incorporates state-of-the-art methods in tele- and brachytherapy. Participants will receive comprehensive imaging assessments and tailored treatment plans to optimize their care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo)therapy including MRI guided BT
* Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix.
* Staging according to FIGO and TNM guidelines
* MRI of pelvis at diagnosis is performed
* MRI, CT or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed
* MRI with the applicator in place at the time of (first) BT will be performed
* Para-aortic metastatic nodes below L1-L2 are allowed
* Patient informed consent

Exclusion Criteria:

* Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin
* Small cell neuroendocrine cancer, melanoma and other rare cancers in the cervix
* Metastatic disease above and beyond the retroperitoneal para-aortic L1-L2 interspace
* Previous pelvic or abdominal radiotherapy
* Previous total or partial hysterectomy
* Combination of preoperative radiotherapy with surgery
* Patients receiving BT only
* Patients receiving EBRT only
* Patients receiving neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/2). However, adjuvant chemotherapy in the form of 4 courses of 3 weekly Carboplatin (AUC 5) and Paclitaxel (155 mg/m2) is allowed according to departmental policy.
* Contra indications to MRI
* Contra indications to BT

Where it's running

• Medical University of Vienna
  Vienna, Austria Recruiting

Study contacts

• Principal investigator: Richard Pötter, MD — Medical University of Vienna
• Study coordinator: Richard Pötter, MD
• Email: richard.poetter@akhwien.at
• Phone: 0043140400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enlonstobart with chemotherapy and radiotherapy for locally advanced cervical cancer

  This study tests whether adding Enlonstobart to standard chemotherapy and chemoradiotherapy helps patients with locally advanced cervical cancer by increasing response rates and monitoring safety.

  Recruiting at 2 sites Phase 4 Tianjin Medical University Cancer Institute and Hospital · Tianjin and 1 other locations · NCT07776821

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Immunotherapy Plus Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer

  This trial tests whether adding immunotherapy and chemotherapy to carbon ion radiotherapy can help women with locally advanced cervical cancer live longer without the cancer growing.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07702838

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• Radiomic MRI model to predict response to chemoradiotherapy in locally advanced cervical cancer

  This project tests whether MRI-based radiomic features can predict how women with locally advanced cervical cancer will respond to combined chemotherapy and radiation.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Nîmes, Gard · NCT07305727

• Post-therapy stress symptoms after gynecologic brachytherapy in cervical cancer

  This study tests whether patients undergoing uterovaginal brachytherapy for cervical cancer develop post-traumatic stress symptoms and how these symptoms change over up to 5 years.

  Recruiting at 2 sites Centre Paul Strauss · Pierre-Bénite and 1 other locations · NCT07204535

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.